KR20240166601A - 공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법 - Google Patents

공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법 Download PDF

Info

Publication number
KR20240166601A
KR20240166601A KR1020247037879A KR20247037879A KR20240166601A KR 20240166601 A KR20240166601 A KR 20240166601A KR 1020247037879 A KR1020247037879 A KR 1020247037879A KR 20247037879 A KR20247037879 A KR 20247037879A KR 20240166601 A KR20240166601 A KR 20240166601A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutical composition
cancer
mutation
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247037879A
Other languages
English (en)
Korean (ko)
Inventor
벤자민 에스. 레인
총-후이 구
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20240166601A publication Critical patent/KR20240166601A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247037879A 2017-11-02 2018-11-02 공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법 Pending KR20240166601A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
US62/580,501 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
KR1020207015661A KR102731624B1 (ko) 2017-11-02 2018-11-02 공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015661A Division KR102731624B1 (ko) 2017-11-02 2018-11-02 공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법

Publications (1)

Publication Number Publication Date
KR20240166601A true KR20240166601A (ko) 2024-11-26

Family

ID=64572453

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247037879A Pending KR20240166601A (ko) 2017-11-02 2018-11-02 공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법
KR1020207015661A Active KR102731624B1 (ko) 2017-11-02 2018-11-02 공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207015661A Active KR102731624B1 (ko) 2017-11-02 2018-11-02 공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법

Country Status (16)

Country Link
US (3) US11345677B2 (https=)
EP (1) EP3704101A1 (https=)
JP (3) JP7335877B2 (https=)
KR (2) KR20240166601A (https=)
CN (2) CN111527076B (https=)
AU (2) AU2018360827B2 (https=)
CA (1) CA3081535A1 (https=)
EA (1) EA202091112A1 (https=)
IL (2) IL305426B2 (https=)
MA (1) MA50526A (https=)
MX (2) MX2020004513A (https=)
PH (1) PH12020550462A1 (https=)
SG (1) SG11202003612VA (https=)
TW (2) TWI839131B (https=)
UA (1) UA127380C2 (https=)
WO (1) WO2019090059A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
AR123228A1 (es) 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Formas en estado sólido de un compuesto orgánico
WO2023192565A1 (en) 2022-03-31 2023-10-05 Servier Pharmaceuticals Llc Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
WO2025060940A1 (zh) * 2023-09-18 2025-03-27 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
WO2025168757A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382354B (es) * 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
CN111527076A (zh) 2020-08-11
US20220363661A1 (en) 2022-11-17
SG11202003612VA (en) 2020-05-28
JP2021501766A (ja) 2021-01-21
JP2024113028A (ja) 2024-08-21
JP7335877B2 (ja) 2023-08-30
US20210198234A1 (en) 2021-07-01
EP3704101A1 (en) 2020-09-09
AU2024203186B2 (en) 2026-04-16
IL274123B2 (en) 2024-01-01
US11851417B2 (en) 2023-12-26
IL305426B2 (en) 2024-10-01
TWI796377B (zh) 2023-03-21
KR102731624B1 (ko) 2024-11-19
UA127380C2 (uk) 2023-08-02
MA50526A (fr) 2020-09-09
US11345677B2 (en) 2022-05-31
US20240343705A1 (en) 2024-10-17
WO2019090059A1 (en) 2019-05-09
CA3081535A1 (en) 2019-05-09
AU2018360827A1 (en) 2020-05-14
AU2024203186A1 (en) 2024-05-30
CN111527076B (zh) 2024-03-12
IL274123A (en) 2020-06-30
JP7499377B2 (ja) 2024-06-13
JP7780576B2 (ja) 2025-12-04
AU2018360827B2 (en) 2024-02-22
TW201930285A (zh) 2019-08-01
PH12020550462A1 (en) 2021-03-22
IL305426B1 (en) 2024-06-01
MX2020004513A (es) 2020-09-17
JP2023093666A (ja) 2023-07-04
TW202337885A (zh) 2023-10-01
CN118359585A (zh) 2024-07-19
MX2022014792A (es) 2023-01-16
IL274123B1 (en) 2023-09-01
IL305426A (en) 2023-10-01
BR112020008598A2 (pt) 2021-01-26
KR20200095480A (ko) 2020-08-10
EA202091112A1 (ru) 2020-07-23
TWI839131B (zh) 2024-04-11

Similar Documents

Publication Publication Date Title
KR102731624B1 (ko) 공결정, 이의 약학적 조성물, 및 이를 포함하는 치료 방법
WO2020092906A1 (en) Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US20250034109A1 (en) Salts, cocrystals, pharmaceutical compositions thereof, and methods of treatment involving the same
US20250041283A1 (en) Cocrystal of an idh1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same
US20220017489A1 (en) Solid dispersions for treatment of cancer
BR112020008598B1 (pt) Cocristal, composição farmacêutica e usos de um cocristal ou de uma composição farmacêutica
CN121969614A (zh) Idh1抑制剂的共晶、其制备方法、其药物组合物及涉及其的治疗方法
EA048730B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA042081B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241113

Application number text: 1020207015661

Filing date: 20200601

PA0201 Request for examination
PG1501 Laying open of application